





The Pharma Initiative Transformative Journey



Integrated Socioeconomic Initiative

Leveraging on the African Continental Free Trade Area (AfCFTA) and African Medicines Agency (AMA), the United Nations Economic Commission for Africa (ECA) in partnership with African Union Commission (AUC), Africa CDC, the African Union Development Agency (AUDA-NEPAD), the Intergovernmental Authority on Development (IGAD), and in collaboration with other relevant United Nations entities, launched the AfCFTA-anchored Pharmaceutical Initiative ("Pharma Initiative") in November 2019.

The Pharma Initiative adopts a three-pronged approach aimed at bolstering sustainable access to equitable, safe, and affordable quality medicines and also facilitating the creation of fiscal space for African countries.



Centralized Pooled Procuremen Mechanism (CPPM) for select SRMNCH commodities Facilitation and advocacy for local pharmaceutical

Ensuring harmonized regulatory and quality standards of medicines

10 Pilot Countries:

Ethiopia, Comoros, Djibouti, Kenya, Madagascar, Mauritius, Rwanda, Seychelles, Sudan & Eritrea























SRMNCH Pilot Products Procurement

Given the disproportionate high maternal and child mortality in Africa, the Pharma Initiative has prioritized 10 priority **Sexual**, **Reproductive**, **Maternal**, **Neonatal & Child Health (SRMNCH)** products for pooled procurement in its proof of concept.



10 Priority SRMNCH Products



Oxytocin, Misoprostol, Zinc Citrate, Amoxicillin, Magnesium Sulphate, Levonorgestrel IUD, Heat-stable Carbetocin, Ergometrine, Labetalol and Clomifene



Africa Pharma Initiative Footprint

1.3 Billion Combined African Population

Consolidated market under the AfCFTA Member States

Forecasted \$259B Pharmaceutical Market by 2030 with potential for 16M jobs

97% of Pharma Products required are currently imported from outside Africa

Harnessing the Demographic Dividend

Promoting access to quality and safe health products by facilitating local production, generating employment for African youth and strengthening the continent's health and economic security Centralized Pooled Procurement
Mechanism (CPPM)



The CPPM Secretariat drawn from pilot Member States is a regional pooled procurement entity established to coordinate aggregated procurement on behalf of Member States.

ECA's Role

Through its think-tank, operational and convening functions, ECA aims to bring together its Member States, development partners & the private sector to:

- Secure a sustained political will of Member States through the signing of a legal agreement for the establishment of a CPPM for health products.
- Leverage experiences and lessons learned from Partners regarding other pooled procurement initiatives and bring them to bear within the Pharma Initiative.
- Facilitate the establishment of a CPPM.
- Facilitate the strengthening of the Member States' regulatory agencies.
- Encourage the ratification and implementation of the African Medicines Agency (AMA) Treaty.
- Facilitate advocacy of local production of pharmaceutical products.



Pharma Initiative from 2019 to Present

Phase I (2019-2020)

- Production of a Situation Analysis & Feasibility Study for Pooled Progurement
- Support to African countries in the context of the COVID-19
 Pandemic (AMSP, AVAT, PAVM)
- Development of a framework for implementing Pooled Procurement Mechanism (PPM)
- Validation & adoption of the Feasibility Study & its framework for PPM by pilot Member States



Upcoming Activities

- ⇒ Country endorsement of CPPM & its legal instrument
- ⇒ Finalisation of the CPPM data platform
- ⇒ CPPM Ministerial Meeting
- ⇒ Implementation of the CPPM pilot procurement (1-5 products)

Phase II (2021-2022)

- Publication of 2 Expressions of Interest (EIOs)
- Technical & GMP Assessments of African-based pharmaceutical manufacturers in line with EIOs
- Technical Assistance to 7 selected manufacturers
- Development of CPPM Information Sharing Platform
- Provision of mandate by pilot countries to the ECA & partners to support the development and implementation of the CPPM
- Production & publication of reports on Good Manufacturing Practices & Pharmaceutical Regulatory Affairs in select countries

Phase III (2023-2024)

- Prioritization of 10 SRMNCH products
- Development of CPPM & its legal instrument
- Convening of an EGM to validate the CPPM & its legal instrument

For further information, please contact: Ms. Jane Karonga: karonga@un.org Mr. Francis Ikome: ikome@un.org